Moderna third-quarter financial results look far better than analysts anticipated, but the beat seems largely to reflect Americans getting their Covid-19 shots earlier this year than they did last year. An earnings beat based on cost cuts and an early launch of this year’s Covid vaccine, however, seems unlikely to change the narrative on the stock, which is down nearly 50% this year coming into Thursday’s session. Net income was $13 million for the quarter, substantially better than the loss of $769 million analysts had anticipated, according to FactSet.